argenx SE
ARGX
View Detailed Chart
825.500USD
-10.890-1.30%
Market hours （ET）Quotes delayed by 15 min
50.49BMarket Cap
39.44P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-1.30%
5 Days
-1.11%
1 Month
+16.00%
6 Months
+32.94%
Year to Date
+34.23%
1 Year
+48.88%
View Detailed Chart
TradingKey Stock Score of argenx SE
Currency: USD Updated: 2025-10-28Key Insights
The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a good stock market performance and strong technicals, the fundamentals don't support the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
argenx SE's Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
25
analysts
Buy
Current Rating
866.340
Target Price
+4.40%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
argenx SE Highlights
StrengthsRisks
argenx SE, formerly arGEN X BV, is a Netherlands-based biopharmaceutical company. It is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 433.23% year-on-year.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Overvalued
The company’s latest PE is 39.34, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 32.61M shares, decreasing 11.61% quarter-over-quarter.
Held by Louis Moore Bacon
Star Investor Louis Moore Bacon holds 47.00K shares of this stock.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
argenx SE Info
argenx SE, formerly arGEN X BV, is a Netherlands-based biopharmaceutical company. It is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.
Ticker SymbolARGX
Companyargenx SE
CEOMr. Tim van Hauwermeiren
Websitehttps://www.argenx.com/
Related Instruments
-10.46%
+0.09%
-0.00%
-1.02%
-0.42%
+1.23%
+2.78%
-3.19%
-5.10%
-0.09%
-0.70%
-2.31%
-0.01%
-0.89%
-1.81%
-3.23%
-1.11%
-3.18%
-3.93%
-4.51%Popular Symbols
